CGEM Soars 36.5% on Analyst Upgrades as Biopharma Pipeline Drives Momentum

Cullinan Therapeutics (CGEM) surged 36.5364% in pre-market trading on November 25, 2025, signaling a sharp reversal in investor sentiment amid evolving analyst dynamics. This follows a series of strategic upgrades from key brokerage firms, positioning the biopharma stock for potential momentum in the coming weeks.

BTIG analyst Julian Harrison led the latest catalyst, raising the price target to $38.00 (a 18.75% increase from $32.00) while maintaining a "Buy" rating. This upgrade builds on a pattern of analyst optimism, including HC Wainwright & Co.’s recent $26.00 price target and Stifel’s reinstated "Buy" at $22.00. The cumulative effect of these ratings has reinforced market confidence, particularly as Cullinan’s clinical-stage pipeline targets oncology and autoimmune diseases with differentiated therapeutic approaches.

The stock’s trajectory reflects broader institutional support, with 9 analysts averaging a $26.00 price target—implying a 118.40% upside from current levels. Despite Morgan Stanley’s August 18 downgrade to $28.00 (a 20% reduction), the overall consensus remains bullish, as evidenced by an average brokerage rating of 1.5 ("Buy"). Analysts appear to value Cullinan’s translational medicine expertise and its ability to identify high-impact disease targets.

Cullinan’s recent momentum appears to have caught the attention of momentum traders and long-term investors alike. With a strong pipeline of drug candidates and a growing number of positive analyst ratings, the stock is showing signs of sustained interest. The company’s focus on unmet medical needs in oncology and autoimmune diseases may continue to drive value creation, especially with its phase II trials showing promising preliminary results.